New Delhi: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that the company will introduce the complete range of Brivaracetam dosage forms at an affordable price for epilepsy treatment in India. Sun Pharma’s brand, Brevipil (Brivaracetam) tablet 25 mg/50 mg/75 mg/100 mg was launched in the market on Day-1 post patent expiry of innovator product (February 21, 2021). Brevipil oral solution (10 mg/ml) and injectable (10 mg/ml) will be available in the market over the next few weeks. Brivaracetam is approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.

Said, Kirti Ganorkar, CEO – India Business, Sun Pharma, “We are introducing the complete range of Brivaracetam in India at a competitive pricing which will improve patient access. This product reaffirms our commitment towards improving epilepsy care by bringing multiple treatment options to patients and health care professionals in India.”  

Brivaracetam belongs to the class of anti-epileptic drugs (AEDs) which have a unique or different mechanism of action compared to the existing treatment options. It has fast onset of action and promising efficacy¹. Long-term studies indicate that the response obtained with the use of Brivaracetam is sustained, with favourable tolerability profile and compliance to the treatment².

While epilepsy is a common neurological disorder, because of the social stigma surrounding epilepsy, cultural practices and poor awareness of new treatment options, management of epilepsy in India continues to be a challenge^3,4. It is estimated that around 5.7 million to 6.4 million people in India suffer from epilepsy^5,6.

BRIVIACT^® is a trademark of UCB.